RM-MET / Metabolic and incretin signalling
Plecanatide
Also known as: Trulance · SP-304
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Plecanatide is a compact disulfide-rich peptide agonist of guanylate cyclase-C. It belongs beside linaclotide in the library, but retains its own identity and product record.
Evidence position
The regulated oral tablet and human trials support Grade A for the named finished product.
What the record does not establish
Oral tablet evidence does not validate a separate peptide sample, alternate route or different formulation.
Sources
- 01Plecanatide compound recordPubChem
- Shows
- Registry identity, structure, formula and synonyms for plecanatide
- Does not show
- Does not establish oral product performance or another material's quality
- 02Trulance prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- U.S. label for a defined oral plecanatide tablet
- Does not show
- Does not describe loose peptide, another route or another formulation
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Plecanatide
- CID
- 70693500
- Formula
- C65H104N18O26S4
- Mass
- 1681.9
PUBMED / FOUND RECORDS
- American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.Gastroenterology / 2023 JunPMID 37211380 / DOI 10.1053/j.gastro.2023.03.214
- Evaluation and Treatment of Constipation in the Geriatric Population.Clinics in geriatric medicine / 2021 FebPMID 33213776 / DOI 10.1016/j.cger.2020.08.007
- American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.The American journal of gastroenterology / 2023 Jun 1PMID 37204227 / DOI 10.14309/ajg.0000000000002227
- Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management.The Medical journal of Australia / 2018 Jul 16PMID 29996755 / DOI 10.5694/mja18.00241
- AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.Gastroenterology / 2022 JulPMID 35738724 / DOI 10.1053/j.gastro.2022.04.016
CLINICALTRIALS.GOV / FOUND RECORDS
- GCC Agonist Signal in the Small IntestineCOMPLETED / PHASE1 / University of Wisconsin, MadisonNCT05107219 / DIRECT intervention MATCH: Plecanatide
- 12-Week Study of Plecanatide for CIC (The National CIC3 Study)COMPLETED / PHASE3 / Bausch Health Americas, Inc.NCT02122471 / DIRECT intervention MATCH: Plecanatide
- The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)COMPLETED / PHASE2 / Bausch Health Americas, Inc.NCT01722318 / DIRECT intervention MATCH: Plecanatide
- Long Term Safety Study of PlecanatideCOMPLETED / PHASE3 / Bausch Health Americas, Inc.NCT02706483 / DIRECT intervention MATCH: Plecanatide
- An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic ConstipationCOMPLETED / PHASE2 / Bausch Health Americas, Inc.NCT03120520 / DIRECT intervention MATCH: Plecanatide